Eli Lilly and Company in combination with Boehringer Ingelheim has developed Jardiance®, a novel therapy to treat patients with heart failure with preserved ejection fraction (HFpEF).
Jardiance is used to lower the blood sugar levels along with diet and exercise in adults with type 2 diabetes, lessens the risk of cardiovascular death in adults with type 2 diabetes and also reduces the risk of hospitalisation for heart failure.
In EMPEROR-Preserved phase III trial, Jardiance has shown 21 per cent of risk reduction of cardiovascular death or hospitalisation for heart failure adults with preserved ejection fraction when compared with placebo.
Some of the common side effects caused by Jardiance® are Ketoacidosis, Dehydration, severe urinary tract infections, low blood sugar, Necrotizing fasciitis, Vaginal yeast infection and allergy.
U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy designation for Jardiance® (empagliflozin) to treat adults with HFpEF.
In US, HFpEF leads for more than 6 million heart failure cases. Currently there are no treatments available which shows significant improvement for patients with HFpEF.
